Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results March 5, 2026 Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026
BearingPoint delivers over €1 billion in revenue for the third year running March 5, 2026 BearingPoint reports strong revenue of €1.026 billion ($1.160 billion) The management and technology consultancy added more than 320 new clients and delivered over 2,200 projects in 26 countries More than 1,000 new colleagues joined the firm, strengthening its global capabilities New products gained significant market traction Strategy 2030 continues to drive future growth and international expansion
Mary Kay Goes for Gold in Global Manufacturing Standards March 4, 2026 Quality, Certified: Mary Kay Achieves ISO 22716
All Seas Capital Backs Sereni to Support Buy-and-Build Growth March 4, 2026 Growth strategy focused on consolidating fragmented markets and expanding geographically
Polares Medical Raises $50 Million Series C to Advance U.S. Expansion of MRace Following Strong Clinical Results March 3, 2026 Financing supported by DC Global Ventures, Lumination Capital, existing investors and a new strategic investor
Ada Doubles YoY Growth as Demand for Agentic Customer Service Surges March 3, 2026 Milestones include innovation in Voice channel, global expansion into Europe and APAC, and large enterprise account wins across industries
Real Chemistry Delivers Double-Digit Year-Over-Year Growth in 2025 as Tier-One, Tech-Enabled Healthcare Commercialization Partner March 2, 2026 Company reported $560 million in 2025 revenue, reflecting continued demand for integrated, AI-enabled solutions from molecule to market
Janus Henderson Confirms Receipt of Unsolicited, Non-Binding Proposal February 26, 2026 No Shareholder Action Required at the Time
Telekom Srbija Group Secures Landmark International Credit Ratings from Fitch and Moody’s, Marking Historic First for Western Balkans February 26, 2026 First Western Balkans–headquartered company to secure dual global credit ratings, shining a spotlight on the region’s rising growth and international relevance
Alkermes plc Announces CEO Succession Plan February 25, 2026 — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors —